Lazard Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.57M | Sell |
|
|||||
|
2025
Q1 | $6.28M | Sell |
|
|||||
|
2024
Q4 | $8.09M | Sell |
|
|||||
|
2024
Q3 | $8.63M | Buy |
|
|||||
|
2024
Q2 | $8.46M | Buy |
|
|||||
|
2024
Q1 | $7.63M | Buy |
|
|||||
|
2023
Q4 | $6.12M | Buy |
|
|||||
|
2023
Q3 | $3.06M | Buy |
|
|||||
|
2023
Q2 | $175K | Sell |
|
|||||
|
2023
Q1 | $4.55M | Buy |
|
|||||
|
2022
Q4 | $505K | Buy |
|
|||||
|
2022
Q3 | $127K | Buy |
|
|||||
|
2022
Q2 | $74K | Sell |
|
|||||
|
2022
Q1 | $74K | Sell |
|
|||||
|
2021
Q4 | $4.13M | Buy |
|
|||||
|
2021
Q3 | $3.27M | Buy |
|
|||||
|
2021
Q2 | – | Sell |
|
|||||
|
2021
Q1 | $88K | Sell |
|
|||||
|
2020
Q4 | $94K | Buy |
|
|||||
|
2020
Q3 | $92K | Sell |
|
|||||
|
2020
Q2 | $142K | Sell |
|
|||||
|
2020
Q1 | $156K | Buy |
|
|||||
|
2019
Q4 | $59K | Sell |
|
|||||
|
2019
Q3 | $129K | Buy |
|
|||||
|
2019
Q2 | $92K | Hold |
|
|||||
|
2019
Q1 | $96K | Hold |
|
|||||
|
2018
Q4 | $78K | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $1.03M | Buy |
|
|||||
|
2017
Q2 | – | Sell |
|
|||||
|
2017
Q1 | $549K | Sell |
|
|||||
|
2016
Q4 | $549K | Sell |
|
|||||
|
2016
Q3 | $2.46M | Sell |
|
|||||
|
2016
Q2 | $3.08M | Buy |
|
|||||
|
2016
Q1 | – | Sell |
|
|||||
|
2015
Q4 | $189K | Sell |
|
|||||
|
2015
Q3 | $233K | Buy |
|
|||||
|
2015
Q2 | $209K | Buy |
|
|||||
|
2015
Q1 | $157K | Buy |
|